AcouSort AB today announced it has received a third order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's novel technology for separation of cells from body fluids.
"We are very pleased to continue this important collaboration, which fits perfectly with our long-term business strategy to become an OEM provider to life science companies within the diagnostic and cell therapy fields, and we are delighted by the swift progression of this project," said AcouSort's CEO Dr. Torsten Freltoft.
The collaboration was originally initiated in mid-autumn 2024 by an order of an AcouSort evaluation kit, and earlier this year, the project continued with an order of additional separation modules to continue the process of evaluating the broader feasibility of AcouSort's technology.
The third order aims to continue building on the product concept and includes additional components (drive modules and separation modules) to be used for prototyping and the product design process.
"There is a great commitment from both sides to take this significant collaboration forward," concludes Dr. Freltoft.
FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing - so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB.
